Analystreport

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) was upgraded by analysts at Roth Capital from a "neutral" rating to a "buy" rating.

FIVE PRIME THERAPEUTICS  (FPRX) 
Last five prime therapeutics earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.fiveprime.com/investor-relations